Revenue from three medicines rose 33% in local currency at Teva, while total revenue fell 2%.
Teva reported Q3 2026 revenues of $4.4B, down 2% YoY, with gross profit margin at 55.5%. Key brands AUSTEDO, AJOVY, and UZEDY grew 33% YoY. Teva raised 2026 revenue outlooks for these brands and acquired BXCL-501. The company also received FDA approval for WELTRUZA and expects peak sales of $1.5B-$2B for its LAI schizophrenia portfolio.
How this was made
The 30-second read
Why it matters
Key decision points for traders are the raised 2026 revenue outlook ranges for AUSTEDO, AJOVY, and UZEDY, the FDA approval of WELTRUZA (long-acting injectable schizophrenia), and the updated financial performance metrics (gross margin, operating income, and free cash flow).
Market read
Guidance raises and a new FDA approval are likely to drive near-term repricing of TEVA’s 2026 earnings trajectory, even as generics competition weighs on total revenue.
What to watch
The outlook includes acquired IPR&D charges and milestone-related adjustments; traders may scrutinize sustainability of margins and whether WELTRUZA peak-sales assumptions translate into near-term cash flow.
Background
Teva frames its quarter as execution of its Pivot to Growth strategy, combining innovative neuroscience growth, biosimilars expansion, and pipeline progress.
Ticker impact
Teva reported Q3 2026 results and raised 2026 revenue outlook, citing WELTRUZA FDA approval and growth in AUSTEDO, AJOVY, and UZEDY.
Likely upward bias as the market reprices TEVA’s 2026 revenue outlook and neuroscience franchise momentum.
The article includes fresh, company-specific disclosures: Q3 revenue/EPS, multiple raised revenue outlook ranges, and a new FDA approval for WELTRUZA, all of which directly affect forward expectations.
Market effects
Reinforces investor focus on neuroscience and long-acting injectable schizophrenia franchises within large pharma, while highlighting ongoing competitive pressure in generics.
Primarily impacts US-listed pharma sentiment; TASE listing may see correlated flows from global guidance repricing.
Moderate global relevance through biosimilars commercialization expansion and US pricing policy commitments (MFN) affecting innovative launch economics.
Counterpoint
The generics decline (notably lenalidomide capsule competition) and GAAP EPS drop could limit upside if investors discount the innovative growth as insufficient to offset the core generics headwind.
Key entities
- companyTeva Pharmaceutical Industries Ltd.
Reported Q3 2026 results, raised 2026 revenue outlook for key innovative brands, and highlighted WELTRUZA FDA approval and biosimilars collaboration.
- productWELTRUZA
FDA-approved long-acting injectable schizophrenia treatment in October 2026, expanding Teva’s LAI franchise.
- partnerSamsung Bioepis
Collaboration to commercialize additional biosimilars (infliximab-abda and etanercept-ykro).
- assetBXCL-501
Acquired from BioXcel Therapeutics, under FDA review for potential at-home use for acute agitation in schizophrenia or bipolar disorder.
